Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

There used to be a time when investors liked to buy biopharma stocks going into product launches. Nowadays, though, expectations seem to run hot on approval and the risk of disappointing launches ...

Contract drug manufacturer Patheon has named former chief executive of Biogen Idec to be the company’s new CEO. James Mullen’s appointment to lead Patheon (TSX:PTI), based in North Carolina’s Research ...

Times are changing for Biogen Idec. The longtime leader in the development of drugs for treating multiple sclerosis just expanded its territory. Last Friday, the Food and Drug Administration granted ...

About Biogen Idec Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders.

Good morning. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Idec Second Quarter 2013 Earnings Conference Call.

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

Biogen Idec Inc. Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the ...

This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an ...

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments ...